Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Entecavir + peginterferon alfa-2a is a combination regimen investigated for the treatment of chronic hepatitis B (CHB). Entecavir is a potent nucleoside analogue that inhibits the hepatitis B virus (HBV) DNA polymerase, effectively suppressing viral replication. Peginterferon alfa-2a is a pegylated biologic that acts as an immunomodulator, stimulating the host's innate and adaptive immune responses to clear the virus. This combination is often studied as a sequential therapy, where entecavir is used to rapidly reduce viral load, potentially restoring immune function and enhancing the subsequent therapeutic effect of peginterferon alfa-2a. Clinical trials, such as the Phase 4 study NCT00917761, evaluate whether this strategy improves rates of HBeAg seroconversion and HBsAg loss compared to monotherapy.
- Brand names
- PegasysBaraclude
- Other names
- entecavir and peginterferon alfa-2aETV + Peg-IFNETV + Peg-IFN alfa-2a
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)POLE (DNA polymerase epsilon)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + peginterferon alfa-2a.